Lipid Anti-Lipid Antibody Responses Correlate with Disease Activity in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disorder characterized by broad clinical manifestations including cardiovascular and renal complications with periodic disease flares and significant morbidity and mortality. One of the main contributing factors to the pathology of SLE is the accumulation and impaired clearance of immune complexes of which the principle components are host auto-antigens and antibodies. The contribution of host lipids to the formation of these autoimmune complexes remains poorly defined. The aim of the present study was to identify and analyze candidate lipid autoantigens and their corresponding anti–lipid antibody responses in a well-defined SLE patient cohort using a combination of immunological and biophysical techniques. Disease monitoring in the SLE cohort was undertaken with serial British Isles Lupus Assessment Group (BILAG) scoring. Correlations between specific lipid/anti-lipid responses were investigated as disease activity developed from active flares to quiescent during a follow up period. We report a significant negative correlation between anti-lipid antibodies for 24S-hydroxycholesterol, cardiolipin and phosphatidylserine with SLE disease activity. Taken together, these data suggest that lipid autoantigens represent a new family of biomarkers that can be employed to monitor disease activity plus the efficacy of therapeutic intervention in SLE.

[1]  A. A. Farooqui,et al.  Changes in cholesterol biosynthetic and transport pathways after excitotoxicity , 2010, Journal of neurochemistry.

[2]  M. Petri,et al.  IgM autoantibodies to distinct apoptosis-associated antigens correlate with protection from cardiovascular events and renal disease in patients with SLE. , 2012, Clinical immunology.

[3]  A. Gerbes,et al.  Role of Kupffer cells in host defense and liver disease , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[4]  M. Sato,et al.  Profile of Autoantibodies Against Phosphorylcholine and Cross-reactivity to Oxidation-Specific Neoantigens in Selective IgA Deficiency With or Without Autoimmune Diseases , 2010, Journal of Clinical Immunology.

[5]  V. Pascual,et al.  The central role of dendritic cells and interferon-alpha in SLE. , 2003, Current opinion in rheumatology.

[6]  G. Tsokos,et al.  Altered signal transduction in SLE T cells. , 2007, Rheumatology.

[7]  N. Goel,et al.  Systemic lupus erythematosus in three ethnic groups: II. Features predictive of disease activity early in its course. LUMINA Study Group. Lupus in minority populations, nature versus nurture. , 1998, Arthritis and rheumatism.

[8]  A. Berthier,et al.  7‐Ketocholesterol‐induced apoptosis , 2005, The FEBS journal.

[9]  R. Voll,et al.  Clearance of apoptotic cells in human SLE. , 2006, Current directions in autoimmunity.

[10]  G. Valesini,et al.  Cardiolipin on the surface of apoptotic cells as a possible trigger for antiphospholipid antibodies , 2000, Clinical and experimental immunology.

[11]  G. Halliday,et al.  Lipid Pathway Alterations in Parkinson's Disease Primary Visual Cortex , 2011, PloS one.

[12]  M. Herrmann,et al.  Predictive value of anti-dsDNA autoantibodies: importance of the assay. , 2008, Autoimmunity reviews.

[13]  D A Isenberg,et al.  Development and initial validation of an updated version of the British Isles Lupus Assessment Group ’ s disease activity index for patients with systemic lupus erythematosus , 2005 .

[14]  G. Kajiyama,et al.  Coronary atherosclerosis and oxidative stress as reflected by autoantibodies against oxidized low-density lipoprotein and oxysterols. , 2001, Atherosclerosis.

[15]  F. Jessen,et al.  Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. , 2000, Journal of lipid research.

[16]  Andrew J. Brown,et al.  Oxysterols: Sources, cellular storage and metabolism, and new insights into their roles in cholesterol homeostasis. , 2009, Molecular aspects of medicine.

[17]  J. Folch,et al.  A simple method for the isolation and purification of total lipides from animal tissues. , 1957, The Journal of biological chemistry.

[18]  C. Lau,et al.  Pathogenesis of systemic lupus erythematosus , 2003, Journal of clinical pathology.

[19]  G. Hughes,et al.  Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome. , 2010, Blood.

[20]  D A Isenberg,et al.  From BILAG to BLIPS—disease activity assessment in lupus past, present and future , 2000, Lupus.

[21]  E. Schned,et al.  Derivation of the SLEDAI. , 1993, Arthritis and rheumatism.

[22]  K. Lauber,et al.  The role of defective clearance of apoptotic cells in systemic autoimmunity , 2010, Nature Reviews Rheumatology.

[23]  J. Ahearn,et al.  Biomarkers for systemic lupus erythematosus: a review and perspective , 2005, Current opinion in rheumatology.

[24]  V. Pascual,et al.  The central role of dendritic cells and interferon-&agr; in SLE , 2003 .

[25]  D. Holdstock.  Past, present--and future? , 2005, Medicine, conflict, and survival.

[26]  R. Dean,et al.  Hydroxypropyl-β-cyclodextrin-mediated Efflux of 7-Ketocholesterol from Macrophage Foam Cells* , 1996, The Journal of Biological Chemistry.

[27]  J. Salmon,et al.  Soluble mediators as therapeutic targets in systemic lupus erythematosus: cytokines, immunoglobulin receptors, and the complement system. , 2006, Rheumatic diseases clinics of North America.

[28]  M. Wenk,et al.  Comparative Plasma Lipidome between Human and Cynomolgus Monkey: Are Plasma Polar Lipids Good Biomarkers for Diabetic Monkeys? , 2011, PloS one.

[29]  I. Björkhem,et al.  Oxysterols in human circulation: which role do they have? , 2002, Current opinion in lipidology.

[30]  D. Russell,et al.  Detecting oxysterols in the human circulation , 2011, Nature Immunology.

[31]  J. Morrow,et al.  A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. Balabanov,et al.  Oxidized phosphatidylcholine is a marker for neuroinflammation in multiple sclerosis brain , 2007, Journal of neuroscience research.

[33]  G. Burmester,et al.  Biomarkers as tools for improved diagnostic and therapeutic monitoring in systemic lupus erythematosis , 2009, Arthritis research & therapy.

[34]  V. M. Holers,et al.  Studies of Filipino patients with systemic lupus erythematosus: Autoantibody profile of first-degree relatives , 2011, Lupus.

[35]  I. Sanz,et al.  Altered B cell receptor signaling in human systemic lupus erythematosus. , 2009, Autoimmunity reviews.

[36]  I. Kosugi,et al.  Endocytosis of soluble IgG immune complex and its transport to lysosomes in hepatic sinusoidal endothelial cells. , 1992, Journal of hepatology.

[37]  M. Petri,et al.  IgM Anti-ß2 Glycoprotein I Is Protective Against Lupus Nephritis and Renal Damage in Systemic Lupus Erythematosus , 2011, The Journal of Rheumatology.

[38]  D. Lütjohann,et al.  Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[39]  L. Wahlund,et al.  Diagnostic use of cerebral and extracerebral oxysterols , 2004, Clinical chemistry and laboratory medicine.

[40]  J. Hillert,et al.  Changes in human plasma levels of the brain specific oxysterol 24S-hydroxycholesterol during progression of multiple sclerosis , 2002, Neuroscience Letters.

[41]  A. Passaro,et al.  Plasma 24S-hydroxycholesterol levels in elderly subjects with late onset Alzheimer's disease or vascular dementia: a case-control study , 2011, BMC neurology.

[42]  J. Wahren,et al.  Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. , 1998, Journal of lipid research.

[43]  I. Durieu,et al.  Paediatric systemic lupus erythematosus: prognostic impact of antiphospholipid antibodies. , 2007, Rheumatology.

[44]  High levels of 15-oxygenated steroids in circulation of patients with multiple sclerosis: fact or fiction? , 2011, Journal of Lipid Research.

[45]  W. Griffiths,et al.  Are 15-oxygenated sterols present in the human circulation?1 , 2011, Journal of Lipid Research.

[46]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[47]  M. Clatworthy,et al.  Biological therapy for lupus nephritis—tribulations and trials , 2010, Nature Reviews Rheumatology.

[48]  N. Siddique,et al.  Marked accumulation of 27-hydroxycholesterol in SPG5 patients with hereditary spastic paresis , 2010, Journal of Lipid Research.

[49]  N. Goel,et al.  Systemic lupus erythematosus in three ethnic groups: II. Features predictive of disease activity early in its course , 1998 .

[50]  Valerio Leoni,et al.  Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis Published, JLR Papers in Press, December 1, 2004. DOI 10.1194/jlr.C400005-JLR200 , 2005, Journal of Lipid Research.

[51]  8-Isoprostaglandin F2 alpha: a potential index of lipid peroxidation in systemic lupus erythematosus. , 2004, Clinical and investigative medicine. Medecine clinique et experimentale.

[52]  B. Winblad,et al.  Marked accumulation of 27-hydroxycholesterol in the brains of Alzheimer's patients with the Swedish APP 670/671 mutation , 2011, Journal of Lipid Research.

[53]  Tim F. Rayner,et al.  Copy number, linkage disequilibrium and disease association in the FCGR locus , 2010, Human molecular genetics.

[54]  D. Sackett,et al.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.

[55]  A. Perl,et al.  Pharmacotherapy of systemic lupus erythematosus , 2009, Expert opinion on pharmacotherapy.

[56]  D A Isenberg,et al.  The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. , 1993, The Quarterly journal of medicine.

[57]  C. Gordon,et al.  Systemic lupus erythematosus: clinical presentations. , 2010, Autoimmunity reviews.

[58]  G. Poór,et al.  Identification of rare anti-phospholipid/protein co-factor autoantibodies in patients with systemic lupus erythematosus , 2009, Autoimmunity.

[59]  D. Isenberg,et al.  Oxidative stress in systemic lupus erythematosus and allied conditions with vascular involvement. , 1999, Rheumatology.

[60]  Y. Chan,et al.  Oxidative damage in Parkinson disease: Measurement using accurate biomarkers. , 2010, Free radical biology & medicine.

[61]  Alvis Brazma,et al.  A CD8 T cell transcription signature predicts prognosis in autoimmune disease , 2010, Nature Medicine.

[62]  L. Jonasson,et al.  7β-hydroxycholesterol induces natural killer cell death via oxidative lysosomal destabilization , 2009, Free radical research.

[63]  I. Bruce,et al.  Development and initial validation of an updated version of the British Isles Lupus Assessment Group ’ s disease activity index for patients with systemic lupus erythematosus , 2005 .

[64]  S. Basu.  F2-isoprostanes in human health and diseases: from molecular mechanisms to clinical implications. , 2008, Antioxidants & redox signaling.

[65]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.